Stephen C. Bain

Active 1994–2025

102
Papers
22,668
Citations
57
h-index
95
i10-index

Citations

Citations per year for Stephen C. Bain1983: 1 citations1994: 5 citations1995: 48 citations1996: 59 citations1997: 77 citations1998: 63 citations1999: 65 citations2000: 57 citations2001: 75 citations2002: 62 citations2003: 44 citations2004: 40 citations2005: 64 citations2006: 53 citations2007: 33 citations2008: 37 citations2009: 35 citations2010: 38 citations2011: 28 citations2012: 33 citations2013: 40 citations2014: 52 citations2015: 60 citations2016: 49 citations2017: 136 citations2018: 213 citations2019: 681 citations2020: 821 citations2021: 865 citations2022: 783 citations2023: 763 citations2024: 1,504 citations2025: 1,103 citations2026: 56 citations1984–1993: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,242 citing papers, 21.1% of this breakdownUnited Kingdom: 1,046 citing papers, 9.9% of this breakdownChina: 580 citing papers, 5.5% of this breakdownItaly: 565 citing papers, 5.3% of this breakdownCanada: 525 citing papers, 5% of this breakdownDenmark: 524 citing papers, 4.9% of this breakdownGermany: 483 citing papers, 4.6% of this breakdownAustralia: 368 citing papers, 3.5% of this breakdownSpain: 281 citing papers, 2.6% of this breakdownFrance: 260 citing papers, 2.5% of this breakdownJapan: 258 citing papers, 2.4% of this breakdownSweden: 234 citing papers, 2.2% of this breakdown
0%21.1%Other 30.5%

Fields

  • Medicine81.5%
  • Biochemistry, Genetics and Molecular Biology13%
  • Immunology and Microbiology1.2%
  • Neuroscience1.2%
  • Health Professions0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • Other2.1%

Topics

  • Diabetes Treatment and Management18.6%
  • Diabetes Management and Research6.9%
  • Pancreatic function and diabetes6.4%
  • Metabolism, Diabetes, and Cancer4.9%
  • Pharmacology and Obesity Treatment3.4%
  • Bariatric Surgery and Outcomes3.3%
  • Other56.5%

Coauthors

All papers

Open in search
  1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 6,603

  2. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 1,932

  3. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

    Authors: , , , , , , - The Lancet Diabetes & Endocrinology 2017 cited by 707

  4. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Enrique Romero Bobillo, Carmen de la Cuesta, Csaba Farsang, Albert Császár, Barbara Zahorska‐Markiewicz, Danuta Pupek-Musialik, Edward Franek, Lucyna Ostrowska, Magdalena Olszanecka‐Glinianowicz, Nebojša Lalić, Dragan Micić, Bernhard Ludvik, Bernhard Paulweber, Rudolf Prager, André Scheen, Luc Van Gaal, Arne Astrup, Kjeld Hermansen, Sten Madsbad, Aila Rissanen, Sakari Nieminen, Markku J. Savolainen, Michel Krempf, Monique Romon, M. Laville, Michel Marre, R Mira, Francis Finucane, Aletha Veenendaal, Frank van Berkum, Solrun Johannsson-Vidarsdóttir, V. Van de Walle, Eelco W. Meesters, Jøran Hjelmesæth, Tor Ole Klemsdal, Bård Kulseng, Birgit Bach-Kliegel, Kurt Laederach, Lukas Villiger, Alain Golay, Stefan Bilz, Thozhukat Sathyapalan, Stephen C. Bain, Sudhesh Kumar, Carel Wynard le Roux, Michael E. J. Lean, Barbara McGowan, Michael E.J. Lean, John Wilding, Gary Wittert, Ian Caterson, Joeseph Proietto, John Prins, Bruno Geloneze Neto, Jorge Luiz Gross, Antônio Roberto Chacra, Alfredo Halpern, Henrique Suplicy, Francis Chun Chung Chow, Hemant Thacker, Manoj Chadha, Hemaraj Chandalia, AG Unnikrishnan, Sanjay Kalra, Neeta Deshpande, Minakshi Shunmugavelu, Vaishali Deshmukh, Maximo Maislos, G. Lieberman, Ilan Shimon and 104 more - The Lancet 2017 cited by 844

  5. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives

    Authors: , , - Diabetes Metabolic Syndrome and Obesity 2021 cited by 427

  6. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

    Authors: , , , , , , , , , , , , - Circulation 2021 cited by 238

  7. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2025 cited by 301

  8. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

    Authors: , , , , , , , - The Lancet Diabetes & Endocrinology 2017 cited by 443

  9. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives

    Authors: , , , , , , , , , , - Advances in Therapy 2021 cited by 305

  10. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

    Authors: , , , , , , , , - Diabetes Obesity and Metabolism 2017 cited by 294

  11. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

    Authors: , - Diabetes Therapy 2020 cited by 273

  12. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review

    Authors: , , , - Diabetes Obesity and Metabolism 2018 cited by 293

  13. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

    Authors: , , , , , , , - Kidney International 2023 cited by 126

  14. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

    Authors: , , , , , , , , - New England Journal of Medicine 2023 cited by 149

  15. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeppe Gram, Claus Bogh Juhl, Janne Hukkanen, Jorma Lahtela, Leo Niskanen, Donal O’Shea, Timothy O’Brien, Séamus Sreenan, Julio Wainstein, Moshe Phillip, Hilla Knobler, Francesco Dotta, Pier Marco Piatti, Roberto Trevisan, Agostino Gnasso, Hanne L. Gulseth, John Cooper, Ewa Pańkowska, Monika Łukaszewicz, Bogumił Wolnik, Isabel Manita, Olinda Marques, Cristina Roque, Rosa Maria Príncipe, Celestino Neves, Susana Heitor, L. A. Ruyatkina, I. V. Dvoryashina, Gulnar Vagapova, Lidiya Belousova, M. Sergeeva-Kondrachenko, А. Б. Песков, Elena Frolova, Albina Golovach, М. А. Куницына, N Krasnopeeva, Irina Ipatko, Carmen De la Cuesta, Francisco J. Tinahones, Mercedes Rigla, Juan Francisco Merino-Torres, Luis Alberto Gómez, Mercè Fernández, Rafael Simó, Mikael Rydén, Johan Jendle, Karin Filipsson, Björn Eliasson, Borys Mankovsky, Iurii Lymar, Liubov Sokolova, Galyna Myshanych, Tetiana Zlova, М.V. Vlasenkо, Petro Kuskalo -, Hamish Courtney, Colin Dayan, Patrick English, Simon Heller, A.B. Johnson, Sunil Nair, Richard David Leslie, Parth Narendran, Nick Oliver, Shenaz Ramtoola, J. H. F. Shaw, Adie Viljoen, Amer Al‐Karadsheh, Jean M. Dostou, Sumana Gangi and 13 more - The Lancet Diabetes & Endocrinology 2021 cited by 178

  16. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

    Authors: , , , , , , - Diabetes Obesity and Metabolism 2020 cited by 209

  17. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

    Authors: , , , , , , , , , , , - Diabetes Care 2020 cited by 169

  18. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure

    Authors: , , , , , , , , , - Journal of the American College of Cardiology 2020 cited by 111

  19. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial

    Authors: , , , , , , , , - Diabetes Care 2018 cited by 131

  20. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

    Authors: , , , , , , , , - Diabetes Care 2015 cited by 228

  21. Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials

    Authors: , , , , , , , , , , , - Diabetes Obesity and Metabolism 2020 cited by 93

  22. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Churn-Ern Yip, Zubin Punthakee, Frédéric Bernier, Heather Lochnan, Vincent Woo, Thomas G. Elliott, Juan Palma, C Merino, Alfredo Danin Vargas, Ulrich Wendisch, Andreas Reichel, Jochen Seufert, Bernd Becker, Hasan Alawi, Andreas L. Birkenfeld, Christoph Hasslacher, Joerg Luedemann, Thomas Schaum, Cornelia Marck, Joachim Sauter, Ulrich Aigner, Yukiko Onishi, Hiroaki Seino, Yuichi Sato, Kiyohide Nunoi, Akira Yamauchi, Eitaro Nakashima, Hiroki Ikeda, Toshihiko Shiraiwa, Yoshimitsu Yamasaki, Hiroki Yokoyama, Kunihiko Nakamura, Masayuki Noritake, Shozo Miyauchi, Tomomi Hakoda, Yoshihide Hirohata, Atsushi Hasegawa, Yoshihide Fukumoto, Hirotaka Nagashima, Masahiro Takihata, Tetsuro Kamada, Hideaki Jinnouchi, Yuri Ono, Takayuki Watanabe, Hiroshi Ohashi, Masahiko Takai, T Seguchi, Katsuya Yamazaki, Hajime Maeda, Shingo Iwasaki, Harold W. de Valk, Adriaan Kooy, S.A.N.T. Landewé-Cleuren, Katarzyna Madziarska, Andrzej Stankiewicz, Katarzyna Wasilewska, Gottfried Rudofsky, Maciej T. Małecki, Ewa Pańkowska, Ewa Szyprowska, Monika Łukaszewicz, Lidia Tokarska, Ирина Аркадьевна Бондарь, I. V. Karpova, Ludmila Ruyatkina, Alsu Gafurovna Zalevskaya, Ruslan Sardinov, Yury Khalimov, Folke Sjöberg, Pekka Koskinen and 63 more - Diabetes Care 2018 cited by 252

  23. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

    Authors: , , , , , , , , - Cardiovascular Diabetology 2019 cited by 162

  24. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke

    Authors: , , , , , , , , , , , , - Circulation 2018 cited by 119